Lilly Reports Solid Second-Quarter 2009 Results, Raises EP... ( INDIANAPOLIS July 22 /- ...)

Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance

Date:7/22/2009

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ --

Increased Volume Drives Revenue Growth Despite Unfavorable Foreign Exchange Impact
Foreign Exchange Movements Lead to Improved Gross Margin Percent
Earnings Rise 20% to $1.06 (reported); 19% EPS Growth to $1.12 (pro forma non-GAAP)
Full-Year 2009 Reported EPS Guidance Range Revised to $4.14 to $4.24 per share
Pro forma non-GAAP EPS Guidance Range Raised to $4.20 to $4.30 per share

Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2009, revised its full-year 2009 earnings per share guidance range to $4.14 to $4.24 on a reported basis, and raised its full-year 2009 pro forma non-GAAP earnings per share guidance range to $4.20 to $4.30 per share.

    $in millions, except per share data         Second Quarter
                                                --------------
                                                2009       2008     % Growth
                                                ----       ----     --------
    Total Revenue - Reported                $5,292.8   $5,150.4           3%
    Net Income - Reported                    1,158.5      958.8          21%
    EPS - Reported                              1.06        .88          20%

    Total Revenue - Pro forma                5,292.8    5,251.2           1%
    Net Income - Pro forma non-GAAP          1,226.7    1,023.4          20%
    EPS - Pro forma non-GAAP                    1.12        .94          19%
                                                ----       ----

Due to significant strateg
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine news :

1. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
2. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
3. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
4. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
5. Lilly Declares Third-Quarter Dividend
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Eli Lilly and Company Announces New Drug Discovery Initiative
8. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
9. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
10. Bart Peterson to Join Lilly Leadership Team
11. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration

Post Your Comments:

Lilly Reports Solid Second-Quarter 2009 Results, Raises EP...( INDIANAPOLIS July 22 /- ...),Health